The global Hashimoto’s Thyroiditis Diagnosis and Treatment Market are anticipated to grow at a considerable CAGR during the forecast period (2021-2027). The key factor to drive the market growth is the increasing prevalence of hypothyroidism among the population. For instance, Hashimoto thyroiditis also known as lymphocytic thyroiditis is the major cause of hypothyroidism in the US where it is mostly seen in women in the region. According to the American Thyroid Association, it has been estimated that around 12.0% of Americans will be developing thyroid conditions in their lifetime in which almost 20 million Americans already have some form of thyroid disease. 60.0% of the US population with thyroid disorder is not aware of their condition. Various government organizations such as the American Thyroid Association, the British Thyroid Foundation, Thyroid Foundation of Canada partnering with many major corporate players for increasing awareness about the diseases and treatment options. For instance, the American Thyroid Association exhibits partnerships with major players such as AbbVie, Horizon, Takeda International, and others. With the help of the corporate leadership council with its partners, it enables open communication between the ATA and the community of corporations about thyroid health.
(Get 15% Discount on Buying this Report)
A full report of Hashimoto’s Thyroiditis Diagnosis and Treatment Market is available at: https://www.omrglobal.com/industry-reports/hashimotos-thyroiditis-diagnosis-and-treatment-market
Rising acquisitions, collaborations among the major players in the market also propel the growth of the market. For instance, in March 2021, Merk a US-based pharma giant acquired Pandion Therapeutics for its TALON technology and immune modulators. Merk acquired Pandion for $1.85 billion and the strategy behind this acquisition was to address the unmet needs of patients suffering from autoimmune diseases. With this acquisition, Merk will be creating a pipeline of diverse candidates that will be activating the natural immune regulatory mechanisms and have chances of achieving better clinical responses for patients with such diseases.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hashimotos-thyroiditis-diagnosis-and-treatment-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
- By Diagnosis
- By Treatment
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- AbbVie Inc., Pfizer Inc, Merck KGaA, and IBSA Institute Biochimique SA
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Hashimoto’s Thyroiditis Diagnosis and Treatment Market Report Segment
By Diagnosis
- Thyroid-Stimulating Hormone Test
- Thyroxine Test
- Antithyroid Antibody Test
By Treatment
- Levothyroxine
- Triiodothyronine
- Desiccated Thyroid Extract
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
